Daewoong Pharma대웅제약
069620 · KOSPI · ₩069620 · 대웅제약
₩99,100▼ ₩1,500 (1.49%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩1.6T | ₩1.4T | ₩1.4T | ₩1.3T | ₩1.2T |
| Cost of sales | ₩748B | ₩689B | ₩687B | ₩641B | ₩608B |
| Gross profit | ₩823B | ₩734B | ₩688B | ₩639B | ₩545B |
| Operating income | ₩197B | ₩148B | ₩123B | ₩96B | ₩89B |
| Net income | ₩193B | ₩23B | ₩120B | ₩39B | ₩30B |
| Net income to shareholders | ₩196B | ₩25B | ₩122B | ₩42B | ₩25B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩2.4T | ₩2T | ₩1.8T | ₩1.6T | ₩1.4T |
| Current assets | ₩732B | ₩613B | ₩575B | ₩549B | ₩525B |
| Cash and equivalents | ₩169B | ₩103B | ₩112B | ₩103B | ₩76B |
| Total liabilities | ₩1.2T | ₩1T | ₩858B | ₩822B | ₩713B |
| Current liabilities | ₩589B | ₩629B | ₩667B | ₩473B | ₩461B |
| Borrowings | ₩827B | ₩646B | ₩437B | ₩439B | ₩438B |
| Total equity | ₩1.1T | ₩927B | ₩912B | ₩741B | ₩702B |
| Shareholders' equity | ₩1T | ₩795B | ₩767B | ₩608B | ₩574B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩149B | ₩51B | ₩136B | ₩118B | ₩40B |
| Capital spending | ₩192B | ₩155B | ₩109B | ₩65B | ₩29B |
| Free cash flow | −₩42B | −₩104B | ₩27B | ₩53B | ₩11B |
| Dividends paid | ₩8.1B | ₩7.7B | ₩7.3B | ₩8.1B | ₩6.5B |
Consolidated where available. Amounts in won.
Also known as: Daewoong Pharma / 대웅제약 / 069620 / KRX:069620
Source: KRX statistical information